- Conditions
- Multiple Myeloma, Hodgkin Disease, Non-Hodgkin Lymphoma
- Interventions
- Acupuncture, opioid, Assessments
- Other · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 299 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 2
- States / cities
- New York, New York • Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1561–1584
of 1,869
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hereditary Hemorrhagic Telangiectasia
- Interventions
- Bevacizumab (Avastin®)
- Drug
- Lead sponsor
- Hanny Al-Samkari, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Liver Transplant Rejection
- Interventions
- CFZ533, Tacrolimus - MMF - corticosteroids
- Biological · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 6 more
- Conditions
- Sphingomyelin Lipidosis
- Interventions
- GZ402665
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- Not listed
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Smoking, Smoking Cessation, Motivation, Nicotine Dependence
- Interventions
- Nicotine Patch, Nicotine Gum, Motivational Interviewing, Smoking Reduction, No Intervention, Nicotine Patch + Nicotine Gum
- Drug · Behavioral · Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 517 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Schizophrenia
- Interventions
- Placebo, RO5545965
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 3
- States / cities
- Garden Grove, California • Glendale, California • St Louis, Missouri
- Conditions
- Diabetes Mellitus, Type 1, Hypoglycemia, Hypoglycemia Unawareness
- Interventions
- Naloxone, Diazoxide, Placebo (for Naloxone), Placebo (for Diazoxide)
- Drug
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 21 Years to 55 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Schizophrenia, Major Depressive Disorder, Bi-Polar Disorder, Schizo Affective Disorder
- Interventions
- ABILIFY MYCITE
- Combination Product
- Lead sponsor
- Durham VA Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 2
- States / cities
- Durham, North Carolina • Houston, Texas
- Conditions
- Refractory Infantile Spasms
- Interventions
- JBPOS0101
- Drug
- Lead sponsor
- Bio-Pharm Solutions Co., Ltd.
- Industry
- Eligibility
- 6 Months to 36 Months
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 17
- States / cities
- Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 13 more
- Conditions
- Low Back Pain, Back Pain, Pain, Chronic Low-back Pain
- Interventions
- Telehealth Mindfulness Program
- Behavioral
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Alcohol Use Disorder
- Interventions
- CMND-100
- Drug
- Lead sponsor
- Clearmind Medicine Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • Baltimore, Maryland
- Conditions
- Temporomandibular Disorders (TMD)
- Interventions
- Standard care, Physical Therapy (PT)
- Other
- Lead sponsor
- Brooke Army Medical Center
- Federal
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Fort Sam Houston, Texas
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Calderasib, Midazolam, Digoxin
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Tourette Syndrome
- Interventions
- NeuroPace RNS® System Deep Brain Stimulator
- Device
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 25 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Mild Cognitive Impairment, Primary Progressive Aphasia, Dementia
- Interventions
- Computerized Cognitive Training, Active tDCS (tDCS) on DLPFC
- Other · Device
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Squamous Cell Carcinoma, Skin Cancer, Keratoacanthoma, Cutaneous Tumor, Skin Cancer, Squamous Cell, Lesion Skin
- Interventions
- Injection of TVEC into target lesions - week 1-2, Injection of TVEC into target lesions 3wks after 1st injection, Injection of TVEC into target lesions 2wks after 2nd injection, Injection of TVEC into target lesions 2wks after 3rd injection
- Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Tucson, Arizona
- Conditions
- CDD
- Interventions
- Fenfluramine Hydrochloride
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Healthy Subjects
- Interventions
- Isavuconazonium sulfate IV, Isavuconazonium sulfate capsules
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Advanced Colorectal Cancer
- Interventions
- MEDI4736
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Spinal Cord Injuries, Obesity, Cardiometabolic Syndrome
- Interventions
- Telenutrition
- Behavioral
- Lead sponsor
- Santa Clara Valley Health & Hospital System
- Other
- Eligibility
- 20 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- San Jose, California
- Conditions
- Pain
- Interventions
- 90 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 45-mg tablets (Treatment A) or one 90-mg tablet (Treatment B).
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Invasive Breast Cancer (Stage I-III), Ductal Carcinoma in Situ, Lobular Carcinoma in Situ, Lobular Carcinoma, Fatigue Related to Cancer Treatment
- Interventions
- Naltrexone, Sugar Pill
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Recurrent Respiratory Papillomatosis
- Interventions
- Avastin® (bevacizumab), Saline
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Insulin Lispro, regular human insulin, recombinant human hyaluronidase PH20, Insulin glargine
- Drug
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 8
- States / cities
- Aurora, Colorado • Miami, Florida • Detroit, Michigan + 5 more